您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > 重组乳腺癌抗雌激素耐药蛋白1
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
重组乳腺癌抗雌激素耐药蛋白1
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。

产品名称
重组乳腺癌抗雌激素药物耐药性基因1(BCAR1)蛋白
Recombinant BCAR1
产品介绍
基因名:

BCAR1


产品别名:

CAS; CAS1; CASS1; CRKAS; P130Cas; BCAR1; BCAR1 scaffold protein, Cas family member; BCAR1 scaffold protein, Cas family member; breast cancer anti-estrogen resistance protein 1; BCAR1, Cas family scaffold protein; BCAR1, Cas family scaffolding protein; Cas scaffolding protein family member 1; Crk-associated substrate p130Cas; 乳腺癌抗雌激素耐药蛋白1; 乳腺癌抗雌激素药物耐药性基因1(BCAR1); 磷酸化乳腺癌抗雌激素耐药蛋白1;


背景信息:
p130 represents one of several known substrates for v-Crk encoded p47. p130 Cas (for Crk-associated substrate) exhibits a high level of tyrosine phosphorylation and is tightly associated with v-Crk, suggesting a role in v-Crk-mediated cell signaling. The molecular cloning of p130 Cas has shown it to represent a novel SH3 containing signaling molecule with a cluster of multiple putative SH2-binding motifs for v-Crk. By immunoprecipitation analysis, p130 Cas has been shown to be highly phosphorylated at tyrosine residues subsequent to either v-Src p60 or v-Crk-mediated transformation and to form stable complexes with both of these transforming proteins. p130 Cas behaves as an extremely potent substrate for protein tyrosine kinases and has been reported to relocate from the cytoplasm to cell membrane upon tyrosine phosphorylation. One proposed model is that the SH2 domain of v-Crk functions to activate c-Src kinase, which in turn phosphorylates p130 Cas.

标签:His-tag   
分类:Recombinant  
类型:Protein   
偶联物:Unconjugated
内毒素水平:按批次,参阅瓶身标签
性状:Liquid
浓度:Batch dependent (Please refer to the vial label for the specific concentration.)
纯化类型:purified
内含物:不含防腐剂
应用:Positive Control;Immunogen;SDS-PAGE;WB.
储存:2-8°C不超过一个月,-80°C不超过12个月。避免反复冻融。
注意事项:仅供实验室使用。不适用于人类或动物的任何临床,治疗或诊断用途。不适合动物或人类食用。